Physician profile
Max Friedlander
NPI 1275028490
$3,050.52
in general payments reported to CMS, 2019-2025
24 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.83 · 2023: $436 · 2024: $1,521 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,037.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.65 | 2023-2025 | |
| Novo Nordisk INC | $390.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $313.17 | 2023-2025 | |
| Exact Sciences Corporation | $209.38 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $207.57 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.88 | 2023-2025 | Xifaxan |
| Amgen INC. | $193.10 | 2023-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.65 | 2023-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $152.54 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $127.60 | 2023-2024 | Rexulti |
| Antares Pharma, INC. | $117.36 | 2024-2025 | Xyosted |
| Astrazeneca Pharmaceuticals Lp | $76.06 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $73.46 | 2024-2025 | Sunosi, Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $44.98 | 2024 | |
| Noven Therapeutics, LLC | $40.78 | 2023-2024 | Xelstrym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $34.96 | 2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $30.53 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $29.64 | 2024 | Veozah |
| Shield Therapeutics INC | $19.00 | 2024 | |
| Lundbeck LLC | $18.86 | 2024 | Rexulti |
| Phadia US INC. | $18.51 | 2023 | Immunocap |
| Halozyme INC | $18.00 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.28 | 2023 | Livalo |
| Merck Sharp & Dohme LLC | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Friedlander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.